SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 574.64 |
| Enterprise Value ($M) | 581.44 |
| Book Value ($M) | 257.80 |
| Book Value / Share | 2.70 |
| Price / Book | 2.23 |
| NCAV ($M) | 215.14 |
| NCAV / Share | 2.25 |
| Price / NCAV | 2.67 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.73 |
| Return on Equity (ROE) | -0.86 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.09 |
| Current Ratio | 7.09 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 270.77 |
| Assets | 313.44 |
| Liabilities | 55.63 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -208.13 |
| Net Income | -192.41 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -153.62 |
| Cash from Investing | -97.82 |
| Cash from Financing | 163.54 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Fairmount Funds Management LLC | 9.90 | -0.31 | |
| 13G | Kynam Capital Management, LP | 6.80 | ||
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 9.99 | 23.67 | |
| 13G/A | Commodore Capital Lp | 7.10 | 25.30 | |
| 13G/A | Point72 Asset Management, L.P. | 6.10 | 47.17 | |
| 13G/A | Ra Capital Management, L.p. | 0.00 | -100.00 | |
| 13G | Vanguard Group Inc | 5.27 | ||
| 13G | Fmr Llc | 6.16 | 460.35 | |
| 13G/A | TCG Crossover GP I, LLC | 6.50 | 55.08 | |
| 13G | Suvretta Capital Management, Llc | 6.40 | ||
| 13G/A | BlackRock Inc. | 7.80 | 36.57 | |
| 13G/A | State Street Corp | 4.82 | -2.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 169,156 | 679,336 | 24.90 | |
| 237,835 | 1,055,110 | 22.54 | |
| 157,822 | 392,916 | 40.17 | |
| 144,225 | 376,531 | 38.30 | |
| 177,655 | 375,291 | 47.34 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CGC – Canopy Growth Corporation | CGEM – Cullinan Therapeutics, Inc. |
| CGON – CG Oncology, Inc. | COLL – Collegium Pharmaceutical, Inc. |
| CPIX – Cumberland Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io